decan-4-olide has been researched along with Disease Models, Animal in 3 studies
*Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fontenla, JA; Gonçalves, DA; Krebs, C; Luft, JG; Pereira, P; Pflüger, P; Regner, GG | 1 |
| Bełtowski, J; Jamroz, A; Wójcicka, G | 1 |
| Cappelari, SE; da Silva Brum, LF; de Oliveira, PA; Lino, FL; Pereira, P; Picada, JN | 1 |
3 other study(ies) available for decan-4-olide and Disease Models, Animal
| Article | Year |
|---|---|
Gamma-decanolactone attenuates acute and chronic seizures in mice: a possible role of adenosine A1 receptors.
Topics: Acute Disease; Animals; Chronic Disease; Disease Models, Animal; Lactones; Male; Mice; Neuroprotective Agents; Receptor, Adenosine A1; Receptors, GABA; Seizures | 2020 |
Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antimetabolites, Antineoplastic; Antioxidants; Aryldialkylphosphatase; Biomarkers; Cholinesterase Inhibitors; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperlipidemias; Isoprostanes; Lactones; Leptin; Male; Models, Cardiovascular; Oxidative Stress; Paraoxon; Phenylacetates; Rats; Rats, Wistar; Statistics as Topic | 2003 |
Effects of gamma-decanolactone on seizures induced by PTZ-kindling in mice.
Topics: Animals; Anticonvulsants; Brain; Comet Assay; Convulsants; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Epilepsy; Kindling, Neurologic; Lactones; Male; Mice; Nerve Degeneration; Pentylenetetrazole; Phenobarbital; Treatment Outcome | 2008 |